XASX
IDT
Market cap11mUSD
Oct 09, Last price
0.04AUD
1D
2.70%
1Q
18.75%
Jan 2017
-78.89%
Name
IDT Australia Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and finished dosage forms. The company furnishes comprehensive analytical support, including the establishment of testing methodologies, stability assessments utilizing specialized chambers, and quality control laboratory services for both chemical and microbiological applications. Furthermore, its service offerings span project management, chemical processing, advanced analytical chemistry, pharmacy support, clinical trial packaging, and regulatory compliance assistance, alongside pharmaceutical development expertise across diverse dosage forms. Notably, IDT Australia also provides medicinal cannabis products and a broad array of contract manufacturing solutions. Established in 1975, the firm is headquartered in Boronia, Australia.
Key people
Executive Chairman of the Board · since 2025
Paul Mcdonald
Chief Executive Officer · since 2023
Mahendran Vasanthakumar
Interim Chief Financial Officer · since 2022
Chris Kagiaros
Head of People and Culture · since 2021
Mark Licciardo
Company Secretary · since 2022
Hugh Burrill
Non-Executive Independent Director · since 2015
Jane Ryan
Non-Executive Independent Director · since 2022
Independent Non-Executive Director · since 2022
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||